Key result
HANC score ≥ 2 identifies ACS patients at high risk for HPR on clopidogrel.
Why the study?
A significant proportion of ACS patients experience high on-treatment platelet reactivity on clopidogrel-based DAPT after PCI, prompting the assessment of key risk factors associated with HPR on clopidogrel versus prasugrel.
Does the HANC score identify Taiwanese ACS patients at high risk for high on-treatment platelet reactivity on clopidogrel?
Cohort (n=200)
Does the HANC score identify Taiwanese ACS patients at high risk for high on-treatment platelet reactivity on clopidogrel?
The HANC score may serve as a useful clinical tool to identify Taiwanese ACS patients at high risk of high on-treatment platelet reactivity on clopidogrel who might benefit from alternative antiplatelet therapy.
Answers are grounded in this paper and cite their sources.
May support HANC score for risk stratification in Taiwanese ACS on clopidogrel; leaves open impact on outcomes and therapy selection.
Background: A significant proportion of acute coronary syndrome (ACS) patients experience high on-treatment platelet reactivity (HPR) on clopidogrel-based dual antiplatelet therapy (DAPT) after percutaneous coronary intervention (PCI). Objectives: This study assessed key independent risk factors associated with significant HPR risk on clopidogrel, but not prasugrel, in the Switch Study cohort of 200 Taiwanese ACS patients who switched from clopidogrel to low-dose prasugrel for maintenance DAPT after PCI. Methods: Univariate analysis and stepwise multivariate logistic regression analysis were conducted to identify key independent risk factors for HPR on clopidogrel, but not prasugrel. Results: A HANC [H: low hemoglobin (< 13 g/dL for men and < 12 g/dL for women); A: age ≥ 65 years; N: non-ST elevation myocardial infarction; C: chronic kidney disease as defined by estimated glomerular filtration rate < 60 mL/min] risk stratification score was developed, and demonstrated optimal sensitivity and specificity at a cutoff score of ≥ 2. The HANC score compared favorably against the recently validated ABCD score in the full Switch Study cohort (n = 200), and the ABCD-GENE score in a genotyped cohort (n = 102). Conclusions: The HANC score may serve to alert clinicians to patients at potentially higher HPR risk on clopidogrel, but not prasugrel. Further research to validate this score and assess its correlation with clinical outcomes is warranted.
No takes yet. Share an insight, caveat, or question.
Lee et al. (2022) conducted a cohort in Acute coronary syndrome (ACS) (n=200). HANC risk stratification score vs. ABCD score and ABCD-GENE score was evaluated on High on-treatment platelet reactivity (HPR) on clopidogrel, but not prasugrel. The HANC risk stratification score demonstrated optimal sensitivity and specificity at a cutoff of ≥ 2 for identifying ACS patients at high risk of on-treatment platelet reactivity on clopidogrel.
Synapse has enriched 10 related papers. Consider them for comparative context: